Altshuler Shaham’s BioMarin Pharmaceuticals BMRN Stock Holding History

Altshuler Shaham’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-256	Closed	-$26.5K	–	383
2022 Q4	$26.5K	Sell	256 -36	-12%	-$3.38K	﹤0.01%	329
2022 Q3	$25K	Buy	+292	New	+$26K	﹤0.01%	349
2022 Q2	–	Sell	-515	Closed	-$40K	–	464
2022 Q1	$40K	Buy	+515	New	+$43.1K	﹤0.01%	408
2020 Q3	–	Sell	-522	Closed	-$64K	–	385
2020 Q2	$64K	Buy	522 +369	+241%	+$36.7K	﹤0.01%	180
2020 Q1	$13K	Buy	153 +145	+1,813%	+$12.5K	﹤0.01%	263
2019 Q4	$1K	Buy	+8	New	+$604	﹤0.01%	423

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Altshuler Shaham's BMRN Position: Q1 2023 in Review

Altshuler Shaham sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 256 shares — an estimated $26.5K sold.

Altshuler Shaham first reported a position in BMRN in Q4 2019 and held it in 6 quarters. The position peaked at $64K in Q2 2020. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Altshuler Shaham reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Altshuler Shaham sold 256 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $26.5K.
Altshuler Shaham first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Altshuler Shaham's BioMarin Pharmaceuticals position peaked at $64K in Q2 2020.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Altshuler Shaham's 13F filing for Q1 2023, filed 9 May 2023.